Your browser doesn't support javascript.
loading
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Catenacci, Daniel V T; Tebbutt, Niall C; Davidenko, Irina; Murad, André M; Al-Batran, Salah-Eddin; Ilson, David H; Tjulandin, Sergei; Gotovkin, Evengy; Karaszewska, Boguslawa; Bondarenko, Igor; Tejani, Mohamedtaki A; Udrea, Anghel A; Tehfe, Mustapha; De Vita, Ferdinando; Turkington, Cheryl; Tang, Rui; Ang, Agnes; Zhang, Yilong; Hoang, Tien; Sidhu, Roger; Cunningham, David.
Afiliação
  • Catenacci DVT; University of Chicago, Chicago, IL, USA.
  • Tebbutt NC; Austin Health, Heidelberg, VIC, Australia.
  • Davidenko I; State Budgetary Healthcare Institution, Clinical Oncology Dispensary #1, Krasnodar Region Ministry of Healthcare, Krasnodar, Russia.
  • Murad AM; Hospital das Clínicas da Universidade Federal de Minas Gerais, Horizonte, Brazil.
  • Al-Batran SE; Institute of Clinical Cancer Research, Krankenhaus Nordwest, University Cancer Center, Frankfurt, Germany.
  • Ilson DH; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Tjulandin S; Russian Cancer Research Center, Moscow, Russia.
  • Gotovkin E; Regional Budgetary Institution of Public Health Ivanovo Regional Oncology Dispensary, Ivanovo, Russia.
  • Karaszewska B; Przychodnia Lekarska Komed Oddzial Jednego Dnia, Konin, Poland.
  • Bondarenko I; Dnipropetrovsk Medical Academy, City Multifield Clinical Hospital 4, Dnipropetrovsk, Ukraine.
  • Tejani MA; University of Rochester Medical Center, James P Wilmot Cancer Center, Rochester, NY, USA.
  • Udrea AA; SC Medisprof SRL, Cluj-Napoca, Romania.
  • Tehfe M; Centre Hospitalier de L'Universite de Montreal Notre-Dame, Montreal, QC, Canada.
  • De Vita F; Second University of Naples School of Medicine, Naples, Italy.
  • Turkington C; Amgen, Cambridge, UK.
  • Tang R; Amgen, Thousand Oaks, CA, USA.
  • Ang A; Amgen, Thousand Oaks, CA, USA.
  • Zhang Y; Amgen, Thousand Oaks, CA, USA.
  • Hoang T; Amgen, Thousand Oaks, CA, USA.
  • Sidhu R; Amgen, Thousand Oaks, CA, USA.
  • Cunningham D; Royal Marsden Hospital, London and Surrey, UK. Electronic address: David.Cunningham@rmh.nhs.uk.
Lancet Oncol ; 18(11): 1467-1482, 2017 11.
Article em En | MEDLINE | ID: mdl-28958504
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Protocolos de Quimioterapia Combinada Antineoplásica / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Humans / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Protocolos de Quimioterapia Combinada Antineoplásica / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Humans / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos